Yissum - Research Development Company of the Hebrew University

Fooling the Virus: A Fusion Protein as Virus-Specific Therapeutic

Posted by Yissum - Research Development Company of the Hebrew UniversityResponsive · Innovative Products and Technologies · Israel

Summary of the technology

Fooling the Virus: The Fusion protein as Virus-Specific Therapeutic
An ACE2 A fusion protein of ACE2 with an Immunogenic Component
Project ID : 47-2020-10877

Yissum - Research Development Company of the Hebrew University

Description of the technology

  • Our laboratory has previously generated fusion proteins of a wide range of viral entry receptors. Among these is ACE2, a membrane-bound enzyme which also serves as the entry receptor for the SARS virus. Study of the novel coronavirus discovered in Wuhan, China has shown striking similarities to the known strains of SARS. This includes work which has suggested that the two viruses share an entry receptor, namely ACE2.
  • Given the immense burden of the novel coronavirus due to its public health threat, development of therapies is critical, we propose use of our fusion protein, which can serve as a decoy receptor for the virus. Attachment of the fusion protein will not only limit its entry into host cells – thereby hampering spread of disease, and acting as a complement-inducing opsinogen for direct viral lysis.
  • We therefore suggest that our fusion protein is not only a useful research tool for studying this deadly virus, but may also hold promise as a virus-specific therapeutic

Project manager

Keren-Or Amar
VP, Business Development, Healthcare

Project researchers

Ofer Mandelboim
HUJI, School of Medicine - IMRIC
Immunology and Cancer Research

Related keywords

  • Biological Sciences
  • Biology / Biotechnology
  • Virus, Virology / Antibiotics / Bacteriology
  • Covid-19
  • Genetic Engineering / Molecular Biology
  • covid-19

About Yissum - Research Development Company of the Hebrew University

Technology Transfer Office from Israel

Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. Founded in 1964 to protect and commercialize the Hebrew University’s intellectual property. Ranked among the top technology transfer companies, Yissum has registered over 8,900 patents covering 2,500 inventions; has licensed out 800 technologies and has spun-off 90 companies. Products that are based on Hebrew University technologies and were commercialized by Yissum generate today over $2 Billion in annual sales.

Send your request

By clicking "Send your request" you are signing up and accepting our Terms of Service and Privacy policy

Technology Offers on Innoget are directly posted and managed by its members as well as evaluation of requests for information. Innoget is the trusted open innovation and science network aimed at directly connect industry needs with professionals online.